Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week open-label study of subcutaneous mepolizumab in pediatric hypereosinophilic syndrome
2021-000933-15Phase 3Active
- Sponsor
- GSK
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mepolizumab in hypereosinophilic syndrome (HES), sponsored by GSK. Primary endpoint: Frequency of HES flares over the 52-week study treatment period. Started Oct 2021; status: active.
02
Drugs
mepolizumab
03
Conditions
hypereosinophilic syndrome (HES)
Beyond the preview
Go deeper on 2021-000933-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000933-15.